查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771486

带状疱疹疫苗市场规模、份额、趋势分析报告（按产品类型、疫苗类型、最终用途、地区、细分市场预测），2025 年至 2030 年

Shingles Vaccine Market Size, Share & Trends Analysis Report By Product, By Vaccine Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

带状疱疹疫苗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球带状疱疹疫苗市场规模预计到2030年将达到112.6亿美元，2025年至2030年的复合年增长率为15.7%。已开发国家带状疱疹发病率的上升以及人们对带状疱疹的认知度的提高，推动了市场规模的扩张。根据美国疾病管制与预防中心(CDC)统计，美国每年通报近一百万例带状疱疹病例。此外，美国三分之一的人一生中都会患上这种疾病。

预计疫苗接种率的提高以及各政府监管机构不断增加的疫苗接种建议将在预测期内推动市场发展。例如，2019年2月，英国疫苗接种联合委员会(JCVI)建议60-70岁成年人使用重组疫苗预防带状疱疹。

带状疱疹疫苗被纳入多个国家的国家免疫计划，预计将推动该疫苗的需求。例如，自2013年以来，带状疱疹疫苗一直是英国国家免疫计画的一部分。英国是欧洲地区第一个将带状疱疹疫苗纳入国家免疫计画的国家，一剂疫苗的费用约为国家医疗服务体系（NHS）的130美元。同样，美国、义大利、澳洲、加拿大多个省份和韩国等其他国家也已将该疫苗纳入其免疫计画。

此外，市场相关人员和监管机构为提高患有该疾病风险族群的认知度而采取的积极措施预计将在未来几年推动市场成长。例如，葛兰素史克公司发起了宣传活动，透过教育人们了解疫苗接种的益处来提高老年人的疫苗接种率。

由于该疫苗的高效性，预计在预测期内将广泛应用。临床试验结果表明， 定序在预防带状疱疹和带状疱疹后遗症神经痛方面非常有效。两剂定序对 50 岁及以上成年人的带状疱疹预防有效率超过 90%。接种疫苗后，该疫苗的保护效力至少可维持四年，且 85% 以上。

疫苗价格低廉，加上已开发国家的高发病率和疫苗接种覆盖率，预计将刺激市场成长。英国、美国、法国、加拿大、德国和韩国的带状疱疹疫苗接种覆盖率高于其他国家。例如，英国的带状疱疹疫苗接种覆盖率最高，超过60%的符合条件的成年人接种了疫苗。

带状疱疹疫苗市场报告重点

  • 2024 年带状疱疹疫苗市场由定序主导，占最大销售份额，为 94.14%。
  • 2024 年，私人医疗保健组织占据带状疱疹疫苗市场的最大收入份额，为 68.33%。
  • 在 2024 年的带状疱疹疫苗市场中，重组疫苗占最大份额，收益占有率为 94.14%。
  • 2024年，北美带状疱疹疫苗市场领先全球市场，占最大收益占有率，达62.26%。

目录

第一章调查方法与范围

第二章执行摘要

3. 带状疱疹疫苗市场变数、趋势和范围

  • 市场介绍/电网展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 带状疱疹疫苗市场分析工具
    • 波特分析
    • PESTEL分析

第四章带状疱疹疫苗市场：产品类型估计和趋势分析

  • 细分仪表板
  • 带状疱疹疫苗市场：2024 年和 2030 年产品类型变化分析
  • 定序
  • 佐斯塔瓦克斯
  • 天空之星

第五章带状疱疹疫苗市场：疫苗类型估计和趋势分析

  • 细分仪表板
  • 带状疱疹疫苗市场：2024 年和 2030 年疫苗类型变化分析
  • 重组疫苗
  • 减毒活疫苗

6. 带状疱疹疫苗市场：最终用途预估与趋势分析

  • 细分仪表板
  • 带状疱疹疫苗市场：2024 年和 2030 年按最终用途分類的变化分析
  • 私人医疗保健机构
  • 政府医疗机构

第七章带状疱疹疫苗市场：区域估计和趋势分析

  • 2024 年及 2030 年各地区市场占有率分析
  • 市场仪表板
  • 市场概述
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • GlaxoSmithKline plc.
    • Pfizer Inc.
    • Merck &Co., Inc.
    • CanSinoBIO
    • Vaccitech
    • Green Cross Corp
    • Geneone Life Science
    • SK Bioscience
Product Code: GVR-4-68039-638-0

Shingles Vaccine Market Growth & Trends:

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Shingles Vaccine Market Report Highlights:

  • The Shingrix segment dominated the shingles vaccine market in 2024, accounting for the largest revenue share of 94.14%.
  • The private healthcare settings segment dominated the shingles vaccine market, accounting for the largest revenue share of 68.33% in 2024.
  • The recombinant vaccine segment accounted for the largest share of the shingles vaccine market in 2024, comprising a revenue share of 94.14%.
  • North America shingles vaccine market led the global market in 2024, holding the largest revenue share of 62.26%

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Shingles Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. shingles vaccine Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Shingles Vaccine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Shingles Vaccine Market: Product Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Shingrix
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Zostavax
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. SKYZoster
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Shingles Vaccine Market: Vaccine Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Shingles Vaccine Market: Vaccine Type Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Recombinant Vaccine
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Live Attenuated Vaccine
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Shingles Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Shingles Vaccine Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Private Healthcare Settings
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Government Healthcare Settings
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Shingles Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. GlaxoSmithKline plc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. CanSinoBIO
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Vaccitech
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Green Cross Corp
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Geneone Life Science
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. SK Bioscience
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global Shingles Vaccines Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 6 Global Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 7 Global Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8 North America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 North America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 11 North America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12 U.S Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 13 U.S Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 14 U.S Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15 Canada Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Canada Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Mexico Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21 Europe Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 Europe Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 25 UK Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 26 UK Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 27 UK Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Germany Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 29 Germany Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 France Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 32 France Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 33 France Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34 Italy Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Italy Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 Spain Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 38 Spain Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 39 Spain Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 41 Denmark Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 44 Sweden Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 46 Norway Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 48 Norway Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 54 Japan Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 55 Japan Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56 China Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 China Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 58 China Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 India Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 India Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 61 India Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 63 South Korea Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 64 South Korea Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65 Australia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 66 Australia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 67 Australia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 69 Thailand Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 70 Thailand Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 73 Latin America Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 74 Latin America Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 76 Brazil Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 77 Brazil Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 79 Argentina Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa Shingles Vaccines Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 86 South Africa Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 92 UAE Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 93 UAE Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Shingles Vaccines Market, By Product, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Shingles Vaccines Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Shingles Vaccines Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Shingles Vaccine market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Shingles Vaccine market: Product outlook key takeaways
  • Fig. 20 Shingles Vaccine market: Product movement analysis
  • Fig. 21 Shingrix market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Zostavax market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 SKYZoster market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Shingles Vaccine market: Vaccine Type outlook key takeaways
  • Fig. 25 Shingles Vaccine market: Vaccine Type movement analysis
  • Fig. 26 Recombinant vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 27 Live attenuated vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 Shingles Vaccine market: End Use outlook key takeaways
  • Fig. 29 Shingles Vaccine market: End Use movement analysis
  • Fig. 30 Private healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 31 Government healthcare settings market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 Key country dynamics
  • Fig. 36 U.S. shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Mexico shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 Europe shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Germany shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 Key country dynamics
  • Fig. 47 France shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Spain shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Sweden shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Norway shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 58 Asia Pacific shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Japan shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 61 Key country dynamics
  • Fig. 62 China shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 63 Key country dynamics
  • Fig. 64 India shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Australia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 67 Key country dynamics
  • Fig. 68 South Korea shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Thailand shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Latin America shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Brazil shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Argentina shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Middle East & Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Africa shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Saudi Arabia shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 83 Key country dynamics
  • Fig. 84 UAE shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Kuwait shingles vaccine market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 87 Market participant categorization
  • Fig. 88 Shingles vaccine market position analysis, 2024
  • Fig. 89 Strategic framework